Barclays Reiterates Overweight Rating on Boston Scientific (BSX), Sees It Well-Positioned for Upside in Q2 and 2H23;
Tweet Send to a Friend
Barclays analyst Matt Miksic reiterated an Overweight rating and $56.00 price target on Boston Scientific (NYSE: BSX)."We hosted a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
